Faculty, Staff and Student Publications
Publication Date
11-1-2024
Journal
Clinical Rheumatology
Abstract
INTRODUCTION: Biologic disease-modifying antirheumatic drugs (bDMARD) are often discontinued when a patient with rheumatoid arthritis (RA) is diagnosed with cancer. Our aim was to determine trends in bDMARD utilization in patients with RA and recently diagnosed cancer.
METHOD: We examined two national claims databases to identify adults with RA and recently diagnosed colorectal, lung, or prostate cancer (Optum's de-identified Clinformatics® Data Mart Database 2008-2022, and Surveillance, Epidemiology, and End Results Program (SEER) Medicare-linked 2008-2017). We determined time trends in bDMARD and tumor necrosis factor inhibitor (TNFi) prescriptions during the first 3 years after cancer with Cochram-Armitage tests and multivariable logistic regression. Cancer cohorts were analyzed separately.
RESULTS: We included 3595 patients in all six cohorts (in Clinformatics® 503 with colorectal, 468 with lung, and 440 with prostate cancer; in SEER-Medicare 580 with colorectal, 1010 with lung, and 594 with prostate cancer). No significant increase was observed in bDMARD or TNFi utilization over time. Overall, use of bDMARD within the first 3 years of follow-up ranged from 16.7% (Clinformatics® lung cohort) to 29.7% (SEER-Medicare colorectal cohort). The major predictor of bDMARD utilization was prior use in the 3 months before cancer diagnosis (p < 0.001 for all cancers) and earlier cancer stage (p < 0.001 in colorectal and lung cancer and p = 0.05 in prostate cancer).
CONCLUSIONS: Use of bDMARD in patients with RA and recently diagnosed common cancers has not increased since 2008. Additional evidence on the safety of bDMARD in patients with early cancer is needed to ensure appropriate management of their RA. Key Points • Use of bDMARD and TNFi in patients with RA and early colorectal, lung, or prostate cancer has been stable since 2008, with no significant increases over time. • The major determinant of receiving bDMARD after cancer diagnosis was prior treatment with bDMARD in the prior 3 months before cancer. • Patients with advanced cancer stage and distant metastases were less likely to receive bDMARD and TNFi than those at early stages of disease.
Keywords
Humans, Male, Arthritis, Rheumatoid, Prostatic Neoplasms, Antirheumatic Agents, Aged, Colorectal Neoplasms, Middle Aged, Lung Neoplasms, Female, United States, SEER Program, Biological Products, Adult, Medicare, Databases, Factual, rheumatoid arthritis, cancer, disease-modifying antirheumatic drugs, tumor necrosis factor alpha inhibitors, drug utilization rates
DOI
10.1007/s10067-024-07135-8
PMID
39230743
PMCID
PMC11822753
PubMedCentral® Posted Date
2-13-2025
PubMedCentral® Full Text Version
Author MSS
Published Open-Access
yes
Included in
Diseases Commons, Gastroenterology Commons, Oncology Commons, Public Health Commons, Rheumatology Commons